Latest Financial Position News

Genesis Minerals has announced a recommended scheme to acquire Magnetic Resources for A$639 million, significantly expanding its gold resource base and advancing its ambitious ASPIRE 500 production goal.

Alfabs Australia reported a 28% revenue rise to $55.6 million in H1 2026, but EBITDA fell due to a $2.8 million Dartbrook mine impact and softer engineering margins. The company is investing heavily in mining hire assets and pursuing a strategic acquisition to drive future growth.

IMDEX Limited has reported its strongest first half ever, with revenue climbing 16% to $247 million, driven by robust market share gains and key acquisitions that broaden its mining technology portfolio.

Cash Converters International Limited reported an 8% rise in half-year revenue to $206.7 million, driven by franchise acquisitions and a shift in lending strategy. Despite a 17% dip in net profit due to one-off costs, the company declared a fully franked interim dividend and reinstated its Dividend Reinvestment Plan.

Cash Converters International Limited has announced the recommencement of its Dividend Reinvestment Plan (DRP) effective 20 February 2026, restoring shareholders’ ability to reinvest dividends into additional shares with favourable terms.

3D Energi Limited remains suspended from ASX trading after failing to provide a crucial update on its funding status and exploration permit implications, prolonging market uncertainty.

Multistack International Limited posted a surprising $2.26 million net profit for 2025, driven by one-off settlement income, while its core operations continue to falter, prompting plans to exit its current business model.

WA Kaolin reported $2.7 million in sales for the December quarter, secured a $1.5 million working capital loan, and restructured $20.4 million of debt, while focusing on plant improvements and cost reductions to address negative margins.

FortifAI Limited has raised $5 million through a strategic placement led by a major Australian institutional fund manager, reinforcing its balance sheet and accelerating its AI development and commercialisation plans.

Cambium Bio has secured FDA clearance to begin Phase 3 dosing for its lead ophthalmology product, Elate Ocular®, alongside key global partnerships and a $2.4 million capital injection from a major shareholder.

Cobram Estate Olives reported a widened half-year loss driven by higher oil costs and operating expenses, while progressing its US growth strategy with a major California acquisition.

AdAlta Limited reported a $2.44 million loss for H1 FY26 while progressing a key CAR-T therapy collaboration and raising $2.8 million in capital. The company’s ‘East to West’ immunotherapy strategy gains momentum with regulatory tailwinds and cost efficiencies.